https://www.selleckchem.com/pr....oducts/momordin-ic.h
However, despite a very promising background, the phase III clinical trial of Trabodenoson failed to achieve the non-inferiority goals of the study. In this review, we discuss different aspects of the abovementioned pathway in ophthalmology and ocular immunology; following a brief evaluation of the current immunotherapeutic strategies, we try to elucidate the links between cancer immunotherapy and glaucoma in order to introduce novel therapeutic targets for glaucoma. Macrophage repolarization from M1 to M2 phenotype is one of the ha
Like
Comment
Share
